Ubs Group Ag Innate Pharma Sa Transaction History
Ubs Group Ag
- $527 Billion
- Q4 2024
A detailed history of Ubs Group Ag transactions in Innate Pharma Sa stock. As of the latest transaction made, Ubs Group Ag holds 3,510 shares of IPHA stock, worth $7,371. This represents 0.0% of its overall portfolio holdings.
Number of Shares
3,510
Previous 8,408
58.25%
Holding current value
$7,371
Previous $19,000
68.42%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding IPHA
# of Institutions
11Shares Held
127KCall Options Held
0Put Options Held
0-
Exchange Traded Concepts, LLC62.8KShares$131,7790.0% of portfolio
-
Morgan Stanley New York, NY43.5KShares$91,4000.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il11.9KShares$24,8910.0% of portfolio
-
Gamma Investing LLC Foster City, CA3.98KShares$8,3470.01% of portfolio
-
Rhumbline Advisers Boston, MA675Shares$1,4170.0% of portfolio
About Innate Pharma SA
- Ticker IPHA
- Exchange OTC
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 79,893,000
- Market Cap $168M
- Description
- Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and periphera...